Shenyang Wansheng Pharmaceutical

Shenyang Wansheng Pharmaceutical is a Chinese pharmaceutical company primarily focused on the development, manufacturing, and commercialization of biopharmaceutical products and small molecule drugs. As a key subsidiary of 3SBio Inc., the company plays a significant role in the production of essential therapies for nephrology, oncology, and hematology. Its product portfolio includes well-known treatments such as recombinant human erythropoietin (EPIAO) and iron sucrose injections for the treatment of anemia. The company operates large-scale manufacturing facilities in Shenyang that comply with international GMP standards, supporting both domestic and international markets. Shenyang Wansheng continues to integrate its research and production capabilities within the broader 3SBio ecosystem to address unmet medical needs in chronic disease management.